Epithelioid hemangioendothelioma in children: The European Pediatric Soft Tissue Sarcoma Study Group experience

Article Pathology

YAP1-TFE3-fused hemangioendothelioma: a multi-institutional clinicopathologic study of 24 genetically-confirmed cases

Josephine K. Dermawan et al.

Summary: YAP1-TFE3-fused hemangioendothelioma is a rare malignant vascular tumor with a female predominance. It commonly occurs in soft tissue and bone. Different histopathological patterns and variable expression of certain proteins, but consistent presence of YAP1-TFE3 gene fusion, were observed. Surgical resection is a common treatment approach and patients generally have a favorable prognosis.

MODERN PATHOLOGY (2021)

Add to Collection

Article Pediatrics

Paediatric non-rhabdomyosarcoma soft tissue sarcomas: the prospective NRSTS 2005 study by the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG)

Andrea Ferrari et al.

Summary: The NRSTS 2005 protocol developed by the European Pediatric Soft Tissue Sarcoma Study Group provides a risk-adapted multimodal standard of care for pediatric non-rhabdomyosarcoma soft tissue sarcomas. Patients in the surgery alone group showed higher event-free survival and overall survival rates, indicating that adjuvant treatment can be safely omitted in low-risk populations.

LANCET CHILD & ADOLESCENT HEALTH (2021)

Add to Collection

Review Oncology

Enithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts

S. Stacchiotti et al.

Summary: Epithelioid hemangioendothelioma (EHE) is a rare vascular sarcoma with variable clinical behavior and systemic involvement. Currently, there are no approved systemic agents specifically for EHE, leading to challenges in treatment selection for patients. In order to address this issue, a global consensus meeting was organized to define evidence-based best practices for the optimal approach to primary and metastatic EHE.

ESMO OPEN (2021)

Add to Collection

Article Oncology